{
    "nctId": "NCT06340165",
    "briefTitle": "A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer",
    "officialTitle": "A Real-world Study of the Efficacy and Safety of Amlotinib for the Treatment of HER2-negative Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 153,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Imaging or tissue/cell puncture, etc. confirmed recurrent, metastatic breast cancer\n* Pathologically confirmed HER-2 negative\n* Application of amlotinib treatment until disease progression or toxicity intolerable, or voluntarily give up the continuation of amlotinib treatment,amlotinib application for at least 2 cycles\n* The clinical data are basically complete\n\nExclusion criteria:\n\n* Patients receiving local treatment means such as surgery and radiotherapy\n* Patients with combined second primary breast cancer and other primary malignant tumors\n* Patients with symptomatic brain metastases",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}